“ASCO strongly opposes provisions in the 2019 Medicare Physician Fee Schedule (MPFS) proposed rule that could significantly cut cancer care resources that are needed to provide high-quality care to individuals with cancer.
“The proposal would trigger major cuts to physician reimbursement for Part B drugs that have been newly introduced to the market and make an already turbulent cancer care delivery system even more unstable. Additionally, the cuts could hinder patient access to newer, innovative therapies—potentially stalling progress against cancer and almost certainly making it more difficult for oncologists to provide essential services to patients with cancer.
“ASCO believes the cuts in the 2019 proposed MPFS rule will harm Medicare beneficiaries with cancer and impede the ability of oncologists to provide the right treatment, to the right patient, at the right time. We urge CMS to abandon this proposal and support robust access to cancer care.”